MORGAN STANLEY PLC/CALL/ELEVANCE HEALTH/475/0.01/21.06.24 Share Price

Warrant

DE000MB92D17

Market Closed - Börse Stuttgart 17:01:42 27/05/2024 BST
0.45 EUR -25.00% Intraday chart for MORGAN STANLEY PLC/CALL/ELEVANCE HEALTH/475/0.01/21.06.24
Current month-23.73%
1 month-31.82%
Date Price Change
27/05/24 0.45 -25.00%
24/05/24 0.6 -10.45%
23/05/24 0.67 -5.63%
22/05/24 0.71 +12.70%
21/05/24 0.63 -7.35%

Delayed Quote Börse Stuttgart

Last update May 27, 2024 at 05:01 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELEVANCE HEALTH, INC.
Issuer Morgan Stanley
WKN MB92D1
ISINDE000MB92D17
Date issued 20/07/2023
Strike 475 $
Maturity 21/06/2024 (25 Days)
Parity 100 : 1
Emission price 0.43
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.71
Lowest since issue 0.21
Delta0.84x
Omega 8.576
Premium0.89x
Gearing10.22x
Moneyness 1.098
Difference Strike -46.41 $
Difference Strike %-9.77%
Spread 0.02
Spread %4.17%
Theoretical value 0.4700
Implied Volatility 37.60 %
Total Loss Probability 18.27 %
Intrinsic value 0.4274
Present value 0.0426
Break even 526.03 €
Theta-0.02x
Vega0x
Rho0x

Company Profile

Elevance Health, Inc. is the American leading of health insurance. The group provides a broad range of medical and specialty products and services (life and disability insurance, medication, dental, vision insurance system and behavioral care insurance system, long-term health care insurance, medical expenses management, etc.). Elevance Health, Inc. is an independent licensee of the Blue Cross and Blue Shield Association, an independent association providing health insurance system. At the end of 2023, the group had nearly 47 million medical members.
Sector
-
More about the company

Ratings for Elevance Health, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Elevance Health, Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
521.4 USD
Average target price
603.3 USD
Spread / Average Target
+15.71%
Consensus